Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents

Journal of Medicinal Chemistry

Volumn 48, Issue 6, 2005, Pages 2218-2228

  Ojima, Iwao ^a   Borella, Christopher P ^a   Wu, Xinyuan ^a   Bounaud, Pierre Yves ^a   Oderda, Cecilia Fumero ^a   Sturm, Matthew ^a   Miller, Michael L ^a   Chakravarty, Subrata ^a   Chen, Jin ^a   Huang, Qing ^a   Pera, Paula ^b   Brooks, Tracy A ^b   Baer, Maria R ^b   Bernacki, Ralph J ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 DEACETYL BACCATIN 3; 14BETA HYDROXYBACCATIN 3; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; MULTIDRUG RESISTANCE; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROPHOBICITY; MITOXANTRONE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PACLITAXEL; STRUCTURE-ACTIVITY RELATIONSHIP; TAXOIDS;

EID: 20144384731     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049483y     Document Type: Article

References (43)

1. Sikic, B. I. Modulation of multidrug resistance: at the threshold. J. Clin. Oncol. 1993, 11, 1629-1635.
2. Croop, J. M. Evolutionary relationships among ABC transporters. Methods Enzymol. 1998, 292, 101-116.
3. Aszalos, A. and Ross, D. D. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. Anticancer Res. 1998, 18, 2937-2944.
4. Frezard, F.; Pereira, M. E.; Quidu, P.; Priebe, W.; Garnier, S. A. P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. Eur. J. Biochem. 2001, 268, 1561-1567.
5. Renes, J.; De Vries, E. G. E.; Nienhuis, E. F.; Jansen, P. L. M.; Muller, M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharmacol. 1999, 126, 681-688.
6. Keppler, D.; Leier, I.; Jedlitschky, G.; Konig, J. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. Chem.-Biol. Interact. 1998, 111-112, 153-161.
7. Deeley, R. G.; Cole, S. P. Function, evolution and structure of multidrug resistance protein (MRP). Semin. Cancer Biol. 1997, 8, 193-204.
8. Scheper, R. J.; Broxterman, H. J.; Scheffer, G. L.; Kaaijk, P.; Dalton, W. S.; Van Heijningen, T. H.; Van Kalken, C. K.; Slovak, M. L.; De Vries, E. G.; Van der Valk, P. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993, 53, 1475-1479.
9. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev. Cancer. 2002, 2, 48-58.
10. Altenberg, G. A. Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily. Curr. Med. Chem.: Anti-Cancer Agents 2004, 4, 53-62.
11. Lee, C. H. Reversing agents for ATP-binding cassette (ABC) transporters: Application in modulating multidrug resistance (MDR). Curr. Med. Chem.: Anti-Cancer Agents 2004, 4, 43-52.
12. Sandor, V.; Fojo, T.; Bates, S. E. Future perspectives for the development of P-glycoprotein modulators. Drug Resist. Updates 1998, 1, 190-200.
13. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981, 41, 1967-1972.
14. Chauffert, B.; Martin, M.; Hammann, A.; Michel, M. F.; Martin, F. Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res. 1986, 46, 825-830.
15. Pearce, H. L.; Safa, A. R.; Bach, N. J.; Winter, M. A.; Cirtain, M. C.; Beck, W. T. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogues that modulate multidrug resistance. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 5128-5132.
16. Ford, J. M.; Prozialeck, W. C.; Hait, W. N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 1889, 35, 105-115.
17. Twentyman, P. R. Modification of cytotoxic drug resistance by nonimmunosuppressive cyclosporins. Br. J. Cancer. 1988, 57, 254-258.
18. Naito, M.; Ohhara, T.; Yamazaki, A.; Danki, T.; Tsuruo, T. Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother. Pharmacol. 1992, 29, 195-200.
19. Kobayashi, J.; Ogiwara, A.; Hosoyama, H.; Shigemori, H.; Yoshida, N.; Sasaki, T.; Li, Y.; Iwasaki, S.; Naito, M.; Tsuruo, T. Taxuspines A-C, new taxoids from Japanese yew Taxus cuspidata inhibiting drug transport activity of P-glycoprotein in multidrug-resistant cells. Tetrahedron 1994, 50, 7401-7416.
20. Kobayashi, J.; Hosoyama, H.; Wang, X.; Shigemori, H.; Sudo, Y.; Tsuruo, T. Modulation of multidrug resistance by taxuspine C and other taxoids from Japanese yew. Bioorg. Med. Chem. Lett., 1998, 8, 1555-1558.
21. Hosoyama, H.; Shigemori, H.; Tomida, A.; Tsuruo, T.; Kobayashi, J. Modulation of multidrug resistance in tumor cells by taxinine derivative. Bioorg. Med. Chem. Lett., 1999, 9, 389-394.
22. Hosoyama, H.; Shigemori, H.; Tomida, A.; Tsuruo, T.; Kobayashi, J. Effects of taxoids from Taxus cuspidata on microtubule depolymerization and vincristine accumulation in MDR cells. Bioorg. Med. Chem. Lett., 1997, 7, 393-398.
23. Ford, J. M.; Hait, W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 1990, 42, 155-199.
24. Gottesman, M. M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62, 385-427.
25. Ojima, I.; Bounaud, P.-Y.; Takeuchi, C.; Pera, P.; Bernacki, R. J. New taxanes as highly efficient reversal agents for multi-drug resistance in cancer cells. Bioorg. Med. Chem. Lett., 1998, 8, 189-194.
26. Geney, R.; Ungureanu, I. M.; Li, D.; Ojima, I. Overcoming multidrug resistance in taxane chemotherapy. Clin. Chem. Lab. Med. 2002, 40, 918-925.
27. Ojima, I., Bounaud, P.-Y. and Bernacki, R. J. New weapons in the fight against cancer. Chemtech 1998, 28, 31-36.
28. Ojima, I., Bounaud, P.-Y. and Oderda, C. F. Recent strategies for the treatment of multi-drug resistance in cancer cells. Exp. Opin. Ther. Pat. 1998, 8, 1587-1598.
29. Ojima, I.; Habus, I.; Zhao, M.; Zucco, M.; Park, Y. H.; Sun, C. M.; Brigaud, T. New and efficient approaches to the semisynthesis of taxol and its C-13 side chain analogues by means of β-lactam synthon method. Tetrahedron 1992, 48, 6985-7012.
30. Magri, N. F.; Kingston, D. G. I.; Jitrangsri, C.; Piccariello, T. Modified taxols. 3. Preparation and acylation of baccatin III. J. Org. Chem. 1986, 51, 3239-3242.
31. Holton, R. A.; Zhang, Z.; Clarke, P. A.; Nadizadeh, H.; Procter, D. J. Selective protection of the C(7) and C(10) hydroxyl groups in 10-deacetyl Baccatin III. Tetrahedron Lett., 1998, 39(19), 2883-2886.
32. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93, 2325-2327.
33. Ojima, I.; Slater, J. C.; Michaud, E.; Kuduk, S. D.; Bounaud, P. Y.; Vrignaud, P.; Bissery, M. C.; Veith, J. M.; Pera, P.; Bernacki, R. J. Syntheses and Structure - Activity Relationships of the Second-Generation Antitumor Taxoids: Exceptional Activity against Drug-Resistant Cancer Cells. J. Med. Chem. 1996, 39, 3889-3896.
34. Ojima, I.; Wang, T.; Miller, M. L.; Lin, S.; Borella, C. P.; Geng, X.; Pera, P.; Bernacki, R. J. Synthesis and structure - activity relationships of new second-generation taxoids. Bioorg. Med. Chem. Lett. 1999, 9, 3423-3428.
35. Marder-Karsenti, R.; Dubois, J.; Bricard, L.; Guenard, D.; Gueritte-Voegelein, F. Synthesis and Biological Evaluation of D-Ring-Modified Taxanes: 5(20)-Azadocetaxel Analogues. J. Org. Chem. 1997, 62, 6631-6637.
36. Brooks, T.; Minderman, H.; O'Loughlin, K. L.; Pera, P.; Ojima, I.; Baer, M. R.; Bernacki, R. J. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol. Cancer Ther. 2003, 2, 1195-1205.
37. Minderman, H.; Brooks, T. A.; O'Loughlin, K. L.; Ojima, I.; Bernacki, R. J.; Baer, M. R. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemother. Pharmacol. 2004, 53, 363-369.
38. Lum, B. L.; Gosland, M. P. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol. Oncol. Clin. N. Am. 1995, 9, 319-336.
39. Murphy, B. R.; Rynard, S. M.; Pennington, K. L.; Grosh, W.; Loehrer, P. J. A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study. Am. J. Clin. Oncol. 1994, 17, 10-13.
40. Mross, K.; Bohn, C.; Edler, L.; Jonat, W.; Queisser, W.; Heidemann, E.; Goebel, M.; Hossfeld, D. K. Randomized phase II study of single-agent epirubicin ± verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society. Ann. Oncol. 1993, 4, 45-50.
41. Hendrick, A. M.; Harris, A. L.; Cantwell, B. M. Verapamil with mitoxantrone for advanced ovarian cancer: a negative phase II trial. Ann. Oncol. 1991, 2, 71-72.
42. Dalmark, M.; Pals, H.; Johnsen, A. H. Doxorubicin in combination with verapamil in advanced colorectal cancer. A phase II trial. Acta Oncol. 1991, 30, 23-26.
43. Okumura, H.; Chen, Z.; Sakou, M.; Sumizawa, T.; Furukawa, T.; Komatsu, M.; Ikeda, R.; Suzuki, H.; Hirota, K.; Aikou, T.; Akiyama, S. Reversal of p-glycoprotein and multidrug-resistance protein-mediated drug resistance in KB cells by 5-O-benzoylated taxinine K. Mol. Pharmacol. 2000, 58 (6), 1563-1569.